Colorectal cancer (CRC) remains the second-leading cause of cancer deaths in the United States, and a new multi-marker test for stool DNA (sDNA) developed by Mayo Clinic in collaboration with Exact Sciences Corp. of Madison, Wis., has seen improvements to the effectiveness of screening for CRC and reducing risk. No special preparations are needed for the test, it can be performed on mailed-in samples. This eliminaties the need for an office visit, and it has provides highly accurate at detecting premalignant polyps and early-stage colorectal cancer.
"We have a mandate to improve effectiveness of screening by better use of existing tools and by creating better tools," says David A. Ahlquist, M.D., of Mayo Clinic. "If one had to start all over, the ideal screening test would be noninvasive and affordable; require no bowel prep, medication restriction or diet change; and would detect neoplasms on both sides of the colorectum with high accuracy."